PMN Form 4: Max Milbury acquires 30,392 shares; holdings rise to 45,389

Rhea-AI Filing Summary

Insider purchase recorded by ProMIS Neurosciences (PMN). On 10/03/2025 Max A. Milbury, an officer serving as Principal Accounting Officer, acquired 30,392 common shares at $0.4912 per share. After the purchase he beneficially owned 45,389 shares. The Form 4 filed and signed on 10/06/2025 reports the transaction as a purchase by one reporting person and shows the ownership as direct. The filing supplies transaction price, share count, role of the reporting person, and post-transaction holdings.

Positive

• Officer purchase of 30,392 shares at $0.4912, increasing direct stake to 45,389
• Timely filing signed on 10/06/2025 reporting the transaction

Negative

• Small absolute purchase size—transaction value is limited (no dollar total exceeds materiality thresholds)
• No derivative grants disclosed to indicate larger potential exposure or future dilution

Insights

Insider Trading Compliance Analyst

Insider compliance: transaction is a straightforward reported purchase by an officer.

The filing shows a purchase of 30,392 common shares at $0.4912 on 10/03/2025 with direct beneficial ownership rising to 45,389 shares. This is a routine Section 16 disclosure that documents the trade and the reporting person’s role as Principal Accounting Officer.

Key dependencies include timely reporting and accuracy of the Form 4; the form is signed on 10/06/2025. Watch for any subsequent filings that modify these holdings or disclose derivative positions.

Equity Governance Specialist

An officer purchase can be viewed as a modest alignment of interest with shareholders.

The transaction increases the officer’s direct stake to 45,389 shares, which is explicitly recorded on the Form 4. The reported price ($0.4912) and share count are concrete data points; no options or derivatives are listed in Table II.

Investor-relevant items to monitor include future insider buys/sells and any material company disclosures that follow this reported purchase within the next 30–90 days.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milbury Max A.

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/03/2025		P		30,392	A	$0.4912	45,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Max A. Milbury	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Max A. Milbury report on Form 4 for ProMIS Neurosciences (PMN)?

He reported a purchase of 30,392 common shares at $0.4912 on 10/03/2025, raising his beneficial ownership to 45,389 shares.

What is Max Milbury’s role at ProMIS Neurosciences (PMN)?

The filing lists him as an Officer with the title Principal Accounting Officer.

Was the Form 4 filed timely and who signed it?

The form shows a signature by Max A. Milbury dated 10/06/2025, which documents the transaction reported on 10/03/2025.

Does the filing disclose any derivative securities for Max Milbury?

No. Table II lists no derivative securities; only a direct purchase of common shares is reported.

How many shares did Milbury own after the reported transaction?

He beneficially owned 45,389 common shares following the reported purchase.